Cure My Disease

Don't miss your cure!

 Log in / Sign up

Experimental drug SHR-A2009 takes first steps against Hard-to-Treat cancers

NCT ID NCT05114759

Ongoing Disease control Sponsor: Suzhou Suncadia Biopharmaceuticals Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jul 16, 2026 · Last updated Jul 17, 2026 · Updated 1 time

Summary

This early-phase trial is testing an experimental drug called SHR-A2009 in people with advanced solid tumors that have stopped responding to standard treatments or have no standard options. The main goals are to find a safe dose and to understand the drug's side effects and how the body processes it. The study will also look for early signs that the drug might shrink tumors.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
an experimental drug called SHR-A2009
What this could lead to
If successful, this could lead to a new treatment option for people with advanced solid tumors who have few alternatives.
What could go wrong
This is a very early Phase 1 trial focused on safety and dosing, so it is unknown if SHR-A2009 will effectively shrink tumors or improve survival. Side effects are also not yet fully understood.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ADVANCED SOLID TUMORS

Contacts and locations

Locations

  • Asan Medical Center

    Seoul, Seoul, 05505, South Korea

  • Chongqing Cancer Hospital

    Chongqicun, Chongqi, 400000, China

  • First Affiliated Hospital of Kunming Medical University

    Kunming, Yunnan, 650000, China

  • Fujian Provincial Cancer Hospital

    Fuzhou, Fujian, 350000, China

  • Guangdong Provincial People's Hospital

    Guangzhou, Guangdong, 510080, China

  • Hunan Cancer Hospital

    Changsha, Hunan, 410000, China

  • National Cancer Center Hospital

    Tokyo, Tokyo, 104-0045, Japan

  • National Cancer Center Hospital East

    Chiba, Chiba, 277-8577, Japan

  • Samsung Medical Center

    Seoul, Seoul, 06351, South Korea

  • Seoul National University Hospital

    Seoul, Seoul, 03080, South Korea

  • Shandong Cancer Hospital&Institute

    Jinan, Shandong, 250000, China

  • Sichuan Cancer Hospital & Institute

    Chengdu, Sichuan, 610000, China

  • The First Hospital of JiLin University

    Changchun, Jlin, 132000, China

  • The Second Affiliated Hospital of Air Force Military University Tangdu Hospital

    Xi’an, Shanxi, 710000, China

  • The Second Affiliated Hospital of Nanchang University

    Nanchang, Jiangxi, 330000, China

  • West China Hospital,Sichuan University

    Chengdu, Sichuan, 610000, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.